Poon, L., de Leval, L., Ng, S. B., Song, Y., Pro, B., Savage, K. J., Ruan, J., Mehta‐Shah, N., & Vose, J. M. (2023). Hematological Oncology journal women in lymphoma special issue: Latest updates in nodal peripheral T‐cell lymphoma. Hematological Oncology. Portico. https://doi.org/10.1002/hon.3191

Kim, W. S., Shortt, J., Zinzani, P. L., Mikhaylova, N., Marin‐Niebla, A., Radeski, D., Ribrag, V., Domenech, E. D., Sawas, A., Alexis, K., Emig, M., Garcia, L., Overesch, A., Pietzko, K., & Horwitz, S. (2023). AFM13 IN PATIENTS WITH CD30 POSITIVE RELAPSED OR REFRACTORY (R/R) PERIPHERAL T CELL LYMPHOMA (PTCL): RESULTS FROM THE PHASE 2 REDIRECT STUDY. Hematological Oncology, 41(S2), 195–196. Portico. https://doi.org/10.1002/hon.3163_126

Jurczak, W., Lamanna, N., Tam, C. S., Kontos, A., Konig, H., Ruppert, A. S., & Tsai, D. E. (2023). COMPARISON OF BLEEDING‐RELATED EVENTS IN PATIENTS WHO RECEIVED PIRTOBRUTINIB WITH AND WITHOUT ANTITHROMBOTIC AGENTS. Hematological Oncology, 41(S2), 758–759. Portico. https://doi.org/10.1002/hon.3165_605

Mehta‐Shah, N., Jacobsen, E. D., Zinzani, P. L., Zain, J., Mead, M., Casulo, C., Gritti, G., Pinter‐Brown, L., Izutsu, K., Waters, S., Brammer, J. E., Pro, B., & Horwitz, S. M. (2023). Duvelisib in patients with relapsed/refractory peripheral T‐cell lymphoma from the phase 2 PRIMO Trial Expansion Phase: outcomes by baseline histology. Hematological Oncology, 41(S2), 499–500. Portico. https://doi.org/10.1002/hon.3164_367

Amengual, J. E., Shyr, Y., Durecki, D., Beumer, J. H., Mansukhani, M. M., Williams, M., Kelleher, N., Cherng, H., Pro, B., Schwartz, G. K., LoRusso, P., & Piekarz, R. (2023). ETCTN P10500: PHASE 1/EXPANSION STUDY OF TAZEMETOSTAT PLUS BELINOSTAT FOR THE TREATMENT OF RELAPSED OR REFRACTORY LYMPHOMA. Hematological Oncology, 41(S2), 833–834. Portico. https://doi.org/10.1002/hon.3166_ot14

Pal, I., Scotto, L., Sabzevari, A., Kinahan, C., Fox, T. E., Feith, D. J., Marchi, E., Loughran, T. P., & O’Connor, O. A. (2023). Identifying the mechanistic differences between hypomethylating agents for the treatment of peripheral T cell lymphoma. Hematological Oncology, 41(S2), 313–314. Portico. https://doi.org/10.1002/hon.3164_220

Fahmy, L. M., Yang, H. R., Zhou, M., Beylergil, V., Schreidah, C. M., Kwinta, B. D., Schwartz, L. H., Fojo, A. T., Bates, S. E., & Geskin, L. J. (2023). LYMPH NODE AND SKIN SCORING GROWTH KINETICS PREDICT OUTCOMES IN CUTANEOUS T‐CELL LYMPHOMA: AN INTERIM ANALYSIS. Hematological Oncology, 41(S2), 772–772. Portico. https://doi.org/10.1002/hon.3165_619

Kater, A. P., Harrup, R., Kipps, T. J., Eichhorst, B., Owen, C. J., Assouline, S., Lamanna, N., Robak, T., Serna, J. d. l., Jaeger, U., Cartron, G., Montillo, M., Mellink, C., Chyla, B., Thadani‐Mulero, M., Lefebure, M., Jiang, Y., Millen, R., Boyer, M., & Seymour, J. F. (2023). MURANO: Final 7 year follow up and retreatment analysis in venetoclax‐rituximab (VenR)‐treated patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL). Hematological Oncology, 41(S2), 239–242. Portico. https://doi.org/10.1002/hon.3163_156

Tolu, S. S., Seshadri, M. R., Chen, Z., Orlando, E., Grenet, J., Toor, R., Sanjurjo, A., Phillips, A., Shore, T., Martin, P., Leonard, J. P., Pro, B., Amengual, J. E., & Ruan, J. (2023). Outcomes of contemporary novel agent incorporation in relapsed/refractory PTCL. Hematological Oncology, 41(S2), 511–512. Portico. https://doi.org/10.1002/hon.3164_377

Lee, H., Choi, M., Siddiqi, T., Rhodes, J., Wierda, W., Isufi, I., Tuscano, J., Lamanna, N., Subbiah, S., Koff, J., Leslie, L., Goldenberg, A., Chung, G., Breitmeyer, J., Yazji, S., Shih, T., Wang, M., Jamieson, C., & Kipps, T. (2023). Phase 1/2 Study of Zilovertamab and Ibrutinib in Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL), or Marginal Zone Lymphoma (MZL). Hematological Oncology, 41(S2), 587–589. Portico. https://doi.org/10.1002/hon.3164_440

Amengual, J. E., Reagan, P., Li, H., Saeed, H., Vaidya, R., Unger, J. M., Danilov, A., LeBlanc, M., Friedberg, J. W., & Smith, S. M. (2023). S2207: RANDOMIZED PHASE II STUDY OF THE ADDITION OF TARGETED AGENTS TO TAFASITAMAB‐LENALIDOMIDE IN TRANSPLANT INELIGIBLE PATIENTS WITH RELAPSED/REFRACTORY LBCL. Hematological Oncology, 41(S2), 842–843. Portico. https://doi.org/10.1002/hon.3166_ot22

Hess, B., Li, H., Hossain, N., Beylergil, V., Sauter, C., Hamadani, M., Svoboda, J., Major, A., Kahl, B., Leonard, J. P., Smith, S., LeBlanc, M., Stiff, P., & Friedberg, J. W. (2023). SWOG 2114: A RANDOMIZED PHASE II TRIAL OF CONSOLIDATION THERAPY FOLLOWING CD19 CAR T‐CELL TREATMENT FOR RELAPSED/REFRACTORY LARGE B‐CELL OR GRADE IIIB FOLLICULAR LYMPHOMA. Hematological Oncology, 41(S2), 839–840. Portico. https://doi.org/10.1002/hon.3166_ot19

Brown, J. R., Eichorst, B., Ghia, P., Jurczak, W., Kahl, B. S., Lamanna, N., Robak, T., Shadman, M., Tam, C. S., Qiu, L., Cohen, A., Zhang, M., Salmi, T., Paik, J., Wang, L., Zhang, J., Ma, H., & Tedeschi, A. (2023). Zanubrutinib safety/tolerability profile and comparison with ibrutinib profile in B‐cell malignancies: Post hoc analysis of a large clinical trial safety database. Hematological Oncology, 41(S2), 459–461. Portico. https://doi.org/10.1002/hon.3164_339

Eichhorst, B., Lamanna, N., O’Brien, S. M., Tam, C. S., Qiu, L., Yang, K., Wu, K., Salmi, T., Barnes, G., & Brown, J. R. (2023). Zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): Impact on health‐related quality of life. Hematological Oncology, 41(S2), 463–464. Portico. https://doi.org/10.1002/hon.3164_341

Flinn, I. W., Jacobson, C. A., Nastoupil, L. J., Morschhauser, F., Davies, A., Buske, C., Corradini, P., Lopez‐Guillermo, A., Reshef, R., Parameswaran, V., Sehgal, A., Tees, M., Lui, C., Xue, W., Beygi, S., Grechko, N., Bolsue, P., Giovanetti, A., To, C., & Nahas, M. (2023). ZUMA‐22: A PHASE 3, RANDOMIZED CONTROLLED STUDY OF AXICABTAGENE CILOLEUCEL (AXI‐CEL) VS STANDARD‐OF‐CARE THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA. Hematological Oncology, 41(S2), 853–855. Portico. https://doi.org/10.1002/hon.3166_ot31